source
- AstraZeneca signs up to $1.7 billion R&D pact with China’s CSPC, marking second deal in six monthsAstraZeneca announced a new research collaboration with Chinese partner CSPC, valued at up to $1.7 billion. The agreement follows a previous large biobucks deal signed less than six months earlier…
- Celea Therapeutics raises $180 million to advance next-generation IPF drug deupirfenidoneCelea Therapeutics, a PureTech Health spinout, announced a $180 million venture round to fund development of its next-generation idiopathic pulmonary fibrosis (IPF) therapy, deupirfenidone. The ro…